NCT02151526View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 7, 2013

Primary Completion Date

February 26, 2019

Study Completion Date

February 26, 2019

Conditions
Beta-Thalassemia MajorSickle Cell Disease
Interventions
DRUG

LentiGlobin BB305 Drug Product

LentiGlobin BB305 Drug Product was administered by intravenous (IV) infusion.

Trial Locations (1)

Unknown

Paris

Sponsors
All Listed Sponsors
lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT02151526 - A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease | Biotech Hunter | Biotech Hunter